What's new? Log in Free sign up

Acelrx Pharmaceuticals (ACRX) News and press releases

Company Profile

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Intraday Session

Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers VIQ Solutions Inc. (NASDAQ: VQS) shares rose 66.8% to $0.3887 in pre-market trading.

12 Health Care Stocks Moving In Thursday's Intraday Session

Recap: AcelRx Pharmaceuticals Q1 Earnings

AcelRx Pharmaceuticals Q1 EPS $(0.75) Beats $(0.78) Estimate

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.78) by 3.85 percent. This is a 37.5 percent increase over losses of $(1.20) per share

Earnings Scheduled For May 10, 2023

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.

AcelRx Pharmaceuticals's Earnings: A Preview

5 Value Stocks In The Healthcare Sector

Stocks That Hit 52-Week Lows On Friday

Friday's session saw 100 companies set new 52-week lows.

Overview Of Value Stocks In The Healthcare Sector

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

AcelRx Pharmaceuticals Q4 EPS $(1.00) Misses $(0.51) Estimate, Sales $252.00K Miss $4.50M Estimate

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.51) by 96.08 percent. This is a 16.67 percent increase over losses of $(1.20) per

Earnings Scheduled For March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's morning session saw 84 companies set new 52-week lows.

Press releases

From Benzinga Pro

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Earnings, Press Releases

Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

HAYWARD, Calif., April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif., April 5, 2023

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a strategic

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

HAYWARD, Calif., March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone payments, and a

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.